title: Oral fungal and bacterial infections in HIV-infected individuals: an overview in Africa.
abstract: Oral opportunistic infections developing secondary to human immunodeficiency virus (HIV) infection have been reported from the early days of the epidemic and have been classified by both the EC-Clearinghouse and the World Health Organisation (WHO). Among the fungal infections, oral candidiasis, presenting in African HIV-infected patients has been sporadically documented. We review the literature with respect to candidal carriage, oral candidiasis prevalence and the predictive value of oral candidiasis for a diagnosis of underlying HIV disease in African HIV-infected patients. The use of oral candidiasis as a marker of disease progression, the species of yeasts isolated from the oral cavity in Africa and the resistance of the yeasts to antifungal agents and treatment regimens are discussed. Orofacial lesions as manifestations of the systemic mycoses are rarely seen in isolation and few cases are reported in the literature from Africa. In spite of the high incidence of noma, tuberculosis, chronic osteomyelitis and syphilis in Africa, surprisingly there have been very few reported cases of the oral manifestations of these diseases in HIV-positive individuals. Orofacial disease in HIV-infected patients is associated with marked morbidity, which is compounded by malnutrition. The authors indicate specific research areas, initially directed at the most effective management strategies, which would complete data in this important area.
authors.affiliation: Department of Oral Medicine, Eastman Dental Institute for Oral Health Care Sciences, University College London, UK. T.Hodgson@eastman.ucl.ac.uk
authors.forename: T A
authors.initials: TA
authors.lastname: Hodgson
authors.forename: C C
authors.initials: CC
authors.lastname: Rachanis
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology*; D000349:Africa / Q000453:epidemiology; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000453:epidemiology; D001424:Bacterial Infections / Q000453:epidemiology*; D015415:Biomarkers; D001759:Blastomycosis / Q000453:epidemiology; D002175:Candida / Q000145:classification; D002180:Candidiasis, Oral / Q000453:epidemiology; D004196:Disease Outbreaks; D018450:Disease Progression; D025141:Drug Resistance, Fungal; D015658:HIV Infections / Q000453:epidemiology; D006660:Histoplasmosis / Q000453:epidemiology; D006801:Humans; D007571:Jaw Diseases / Q000453:epidemiology; D009059:Mouth Diseases / Q000453:epidemiology* / Q000382:microbiology; D009181:Mycoses / Q000453:epidemiology*; D009625:Noma / Q000453:epidemiology; D009748:Nutrition Disorders / Q000453:epidemiology; D010019:Osteomyelitis / Q000453:epidemiology; D015995:Prevalence; D013587:Syphilis / Q000453:epidemiology; D014393:Tuberculosis, Oral / Q000453:epidemiology
chemical_list: D000935:Antifungal Agents; D015415:Biomarkers